178 filings
Page 2 of 9
8-K/A
twofi609th vasbqmc
28 Oct 22
Other Events
4:05pm
8-K
mmcf0ut 1il
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
rt86b0 96yg1
11 Oct 22
Aravive Receives Third Development Milestone from 3D Medicines
7:05am
8-K
16jhpdy710riley r4b
27 Sep 22
Regulation FD Disclosure
7:05am
8-K
az99ukm
22 Sep 22
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
nu70gomjg
26 Aug 22
Regulation FD Disclosure
4:06pm
8-K
pzzd5r
26 Aug 22
Regulation FD Disclosure
7:05am
8-K
elqefaai
11 Aug 22
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
7:15am
8-K
48b mzovfpxvug08xj23
11 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:05am
8-K
95ynpj
5 Jul 22
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
7:05am
8-K
yw3l47l29mp4s8wqrexl
3 Jun 22
Aravive Appoints Rudy Howard as Chief Financial Officer
4:06pm
8-K
9d6d xxv5w53ki3
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
y8v16wl360l2btrs w0k
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
a2cu jsv04xj
11 May 22
Regulation FD Disclosure
7:01am
8-K
cka ejlgcdsot1qul
4 Apr 22
Submission of Matters to a Vote of Security Holders
4:16pm
8-K
m5rpkdux zidqe9
1 Apr 22
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:05am
8-K
a732 sug3
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
8-K
ocl qscpw6z0
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
8-K
wf6yt36g7tuunqfl
25 Mar 22
Departure of Directors or Certain Officers
4:07pm
8-K
xe6u5
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm